LYEL Lyell Immunopharma, Inc.
USHealthcareAs of 2026-07-02
Why LYEL matters now
Lyell Immunopharma, Inc. (LYEL) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.05 with +8.33% on the session and $327.8M in market capitalization; recent performance reads 1-month -21.02% and YTD -58.61%.
The latest financial table shown here is Q1 2026, with revenue of $2.0K, net income of $-24.2M, and EPS of $-1.10. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -45.2%.
The latest indexable market news headline is "Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $47.00; recent insider activity includes Innovative Cellular Therapeutics Holdings Ltd filing J-Other. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.02
P/S
9589.56
EV/EBITDA
-1.07
DCF Value
$0.35
FCF Yield
-45.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-7422.6%
Operating Margin
-618909.7%
Net Margin
-794858.1%
ROE
-85.7%
ROA
-70.3%
ROIC
-59.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.0K | $-24.2M | $-1.10 |
| Q4 2025 | $6.0K | $-140.7M | $-6.62 |
| FY 2025 | $36.0K | $-274.4M | $-16.06 |
| Q3 2025 | $15.0K | $-38.8M | $-2.13 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$47.00
Target (Median)
$47.00
Target Range
$45.00 - $49.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.09
Lyell Immunopharma, Inc. (LYEL) is a firm specializing in T cell reprogramming, dedicated to crafting T cell therapies for individuals battling solid tumors. The company's therapeutic innovation relies on advanced technology platforms: Gen-R, an ex vivo genetic reprogramming technique engineered to counteract T cell exhaustion, and Epi-R, an ex vivo epigenetic reprogramming method designed to cultivate T cells with sustained stem-like properties. Its development pipeline features notable candidates such as LYL797, a T cell product aimed at non-small cell lung cancer and triple-negative breast cancers; LYL845, intended for a broad range of solid tumors; and NY-ESO-1, focusing on synovial sarcoma and other specific solid tumor conditions. Additionally, Lyell holds a research and development collaboration and licensing agreement with GlaxoSmithKline for the NY-ESO-1 initiative. Founded in 2018, the company's main office is situated in South San Francisco, California.